Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers

a technology of neoplastic disease and chemotherapy, applied in the direction of drug compositions, peptides, chemical treatment enzyme inactivation, etc., can solve the problems of limited utility of traditional chemo and radiotherapy for the treatment of tumors, high level of cellular toxicity, and limited therapeutic advantage, so as to reduce the side effects of cancer therapy and other types of stress, increase the chemo and/or radiosensitivity of a mammalian cell, and reduce the effect of side effects of cancer

Inactive Publication Date: 2005-12-22
WU BIN +2
View PDF2 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0008] Other embodiments provide methods of increasing the chemo and / or radiosensitivity of a mammalian cell, methods of reducing the side effects of cancer therapy and other types of stress associated with p53 induction and methods of treating neoplastic disease.

Problems solved by technology

Traditional chemo and radiotherapy for the treatment of tumors is limited in utility by the absence of target specificity.
Unfortunately, very few selective agents are available for the many tumor types and where selective agents do exist, the therapeutic advantage has been minimal.
Owing to the non-specific nature of these and other currently available “sensitizers,” however, normal, non-neoplastic cells are subject to increased chemotherapy and radiation sensitivity thus resulting in a high level of cellular toxicity.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers

Examples

Experimental program
Comparison scheme
Effect test

example 1

Expression of KIAA0175 mRNA

[0124] This example discloses Northern blot analysis of the tissue- and cancer cell-specific expression of KIAA0175 mRNA.

[0125] A KIAA0175 specific DNA probe was generated from a 0.7 kb internal fragment of the KIAA0175 open reading frame. This DNA fragment was radiolabeled with α-32P-ATP by standard methods (Stratagene; La Jolla, Calif.) and was used to probe commercially available tissue- and cancer cell-line blots obtained from Clontech (7760-1, 7759-1, and 7757-1). Specific hybridization of the KIAA0175 probe was detected by autoradiography.

[0126] Of the various tissues tested by Northern blot analysis, testis expressed the highest level of KIAA0175 mRNA. Thymus and colon expressed a lower level of KIAA0175 mRNA followed, in order of decreasing expression, by placenta and spleen. Of the various cancer cell lines examined, MOLT-4 showed the highest levels of KIAA0175 mRNA followed by HeLa S3, K562, and SW480 cells, that expressed intermediate levels ...

example 2

Autophosphorylation of the KIAA0175 Protein

[0127] This example discloses that KIAA0175 possesses an autophosphorylation activity and that this activity may be eliminated by a single amino acid substitution at lysine-40.

[0128] Plasmid constructs expressing the KIAA0175 wild-type and the kinase inactive K40A mutant protein were prepared. These plasmids express both KIAA0175 variants as hemagglutinin (HA) fusion proteins thereby facilitating their isolation via immunoprecipitation and detection through Western hybridization.

[0129] The plasmid vector pcDNA3.1 (Invitrogen) contains a multiple cloning site and CMV promoter to facilitate the subcloning and expression the KIAA0175 cDNAs having an HA tag sequence.

[0130] Cos 7 cells were transfected with either the naked vector pcDNA3.1 or the pcDNA3.1 expressing the wild-type or kinase inactive KIAA0175 proteins. The KIAA0175 proteins were immunoprecipitated with anti-HA monoclonal antibody (COVANCE / Babco). Kinase activity was determined...

example 3

Recombinant and Endogenous KIAA0175 Protein Levels After Exposure of Cells to γ-Irradiation and Hydroxyurea

[0132] This Example discloses that KIAA0175 protein levels increase following exposure of cells expressing either recombinant or endogenous KIAA0175 to γ-irradiation or hydroxyurea.

[0133] Recombinant HA-KIAA0175 protein levels in Cos 7 cells were detected either without treatment or after treatment with either γ-irradiation or hydroxyurea. Lysates were loaded directly onto SDS polyacrylamide gels without prior immunoprecipitation of the HA fusion proteins. The HA-fusion proteins were detected by probing with anti-HA antibodies.

[0134] Similarly, endogenous KIAA0175 protein levels in cells were detected either without treatment or after treatment with either γ-irradiation (HeLa cells) or hydroxyurea (Arent cells). Lysates were loaded directly onto SDS polyacrylamide gels without prior immunoprecipitation of the KIAA0175 proteins. The KIAA0175 proteins were detected by probing ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
timeaaaaaaaaaa
transfection timeaaaaaaaaaa
genomic stabilityaaaaaaaaaa
Login to View More

Abstract

Inhibitors of KIAA0175 are provided that reduce the expression or biological activities of KIAA0175, p53 and / or p21 in a mammalian cell. KIAA0175 inhibitors include anti-sense molecules, ribozymes, antibodies and antibody fragments, proteins and polypeptides as well as small molecules. KIAA0175 inhibitors find use in compositions and methods for decreasing KIAA0175, p53 and / or p21 gene expression as well as methods for increasing the chemo and / or radiosensitivity of mammalian cells, including tumor cells, methods for decreasing the side effects of cancer therapy and methods for treating neoplastic diseases.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application is a Divisional of U.S. patent application Ser. No. 09 / 870,937 filed May 30, 2001, which claims priority from U.S. Patent Application No. 60 / 208,435 filed May 31, 2000, which is incorporated by reference herein in its entirety.TECHNICAL FIELD [0002] This invention relates generally to regulation of the cell cycle and cell death following exposure to agents that cause DNA damage. More specifically, the present invention provides compositions and methods for inhibiting KIAA0175 gene expression and / or biological activity as well as for reducing the expression and / or activation of p53, p21 or related proteins. Such compositions and methods are useful as chemotherapy and radiation sensitizers and, as a consequence, find utility in the treatment of neoplastic disease. BACKGROUND OF THE INVENTION [0003] Traditional chemo and radiotherapy for the treatment of tumors is limited in utility by the absence of target specificity. Me...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C12N15/09A61K31/7088A61K31/7105A61K38/00A61K38/55A61K39/395A61K48/00A61P35/00A61P43/00C12N9/12C12N9/99C12N15/113
CPCA61K38/00C12N9/1205C12Y207/01037C12N2310/11C12N15/1137A61P35/00A61P43/00
Inventor WU, BINSEELEY, TODDWILLIAMS, LEWIS
Owner WU BIN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com